Brachytherapy
Volume 5, Issue 4 , Pages 256-261 , October 2006

A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?

  • Johann I. Tang

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute, National University Hospital, Singapore
    • ,
  • Scott G. Williams

      Affiliations

    • Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Victoria 8006, Australia. Tel.: +61-3-9656-1111; fax: +61-3-9656-1424.
    • ,
  • Keen Hun Tai

      Affiliations

    • Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    • ,
  • Joanne Dean

      Affiliations

    • Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    • ,
  • Gillian M. Duchesne

      Affiliations

    • Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

Received 27 July 2006 ,Revised 28 August 2006 ,Accepted 29 August 2006.

References 

  1. Leith JT. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate. 1994;24:119–124
  2. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  3. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  4. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  5. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316–327
  6. Sobin LH, Wittekind C. International Union against Cancer. TNM classification of malignant tumors. 5th ed.. New York: J. Wiley; 1997;
  7. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  8. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  9. Duchesne GM, Das R, Toye W, et al. Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. Australas Radiol. 2002;46:384–389
  10. Lee SP, Leu MY, Smathers JB, et al. Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys. 1995;33:375–389
  11. Kestin LL, Martinez AA, Stromberg JS, et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol. 2000;18:2869–2880
  12. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  13. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  14. Williams SG. Characterization of the behavior of three definitions of prostate-specific antigen-based biochemical failure in relation to detection and follow-up biases: Comparison with the American Society for Therapeutic Radiology and Oncology consensus definition. Int J Radiat Oncol Biol Phys. 2006;64:849–855
  15. Martinez AA, Demanes DJ, Galalae R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005;62:1322–1331
  16. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  17. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252

 This study was presented at the Royal Australian and New Zealand College of Radiologists annual scientific meeting, Sydney, 2005.

PII: S1538-4721(06)00252-2

doi: 10.1016/j.brachy.2006.08.007

Brachytherapy
Volume 5, Issue 4 , Pages 256-261 , October 2006

Article Tools

* Image Usage & Resolution